Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

X.e

X - Systemic/Distant conditions, syndromes and reactions

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

Last update 07/03/2021

Corresponds to circulating autoantibodies (ANA, anti-dsDNA, multispecific ANCA). Titers can be very high and/or multispecific and tend to diminish in a few weeks or months upon drug discontinuance. Autoimmunity can be asymptomatic or is with various clinical presentations including pulmonary vascultis or hemorrhage (PMID 20015613). See also under patterns IIIa, IIIb, IIId, Vd, VId, and Xb, d, h, j, m, s, x, y, ac, ah, am, ao, aw, ax, ay

Causative drugs

24

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Abatacept
I.b
II.e
X.e
Adalimumab
I.a
I.b
I.c
I.e
I.g
I.n
I.x
I.aa
II.e
III.a
III.d
IV.a
VI.d
VI.m
IX.j
X.b
X.d
X.e
X.l
X.m
X.u
XII.a
XII.s
XVI.e
XVI.k
XIX.a
XIX.d
XIX.f
XX.a
XX.b
XX.c
XX.e
XX.f
XX.g
XX.y
XX.z
Alemtuzumab
I.a
I.b
II.a
II.e
III.a
IV.a
VII.b
X.e
X.i
X.m
X.ae
X.ap
XIX.a
XIX.o
XX.b
XX.e
XX.h
XX.m
XXI.b
Antithyroid drugs
X.e
X.u
XI.l
Antiviral therapy/agents (direct-acting) against hepatitis C virus
I.a
I.b
II.e
III.a
IV.ab
VI.a
X.e
XI.c
XVI.b
XVIII.a
XVIII.b
XVIII.c
XIX.o
XX.f
Breast implants - Augmentation mammaplasty (w/wo evidence for leakage/rupture)
I.a
I.c
I.o
I.am
I.an
II.u
III.a
VI.a
VI.w
VI.x
VIII.a
VIII.e
VIII.o
X.e
X.j
X.l
X.m
X.o
X.s
X.u
X.af
XII.c
XVI.k
XVI.ax
XVI.bk
XVII.c
XIX.af
XIX.aj
XIX.bq
XIX.cx
XXI.f
XXI.h
XXI.i
Clozapine
I.a
I.c
IV.a
V.a
VI.a
VI.b
VI.m
VII.a
IX.f
X.e
X.q
X.u
X.w
XI.h
XI.l
XI.ah
XII.d
XII.g
XII.i
XII.ak
XIX.bu
XIX.cp
Etanercept
I.a
I.e
I.g
I.n
I.r
I.x
I.z
III.a
IV.a
V.a
VI.d
VI.f
VI.m
VII.a
VII.d
VIII.a
IX.q
X.b
X.d
X.e
X.f
X.l
X.m
X.o
X.u
X.ae
X.at
XI.aa
XII.d
XIX.a
XIX.d
XIX.f
XIX.bx
XX.a
XX.b
XX.f
XX.g
XX.h
XX.aa
Hydralazine
I.a
I.b
I.e
II.e
III.a
III.b
III.d
IV.a
IV.i
V.a
V.c
V.f
VI.d
VI.i
VI.m
VII.d
X.a
X.b
X.d
X.e
X.o
X.q
X.u
X.am
XII.c
XII.l
XIX.o
Hydrochlorothiazide
I.a
I.b
I.d
II.a
II.b
II.c
II.e
II.h
II.k
IX.h
X.b
X.c
X.d
X.e
X.w
XI.b
XII.c
XII.o
XII.u
XXIII.a
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.v
I.w
I.x
I.z
I.ab
I.ae
I.ak
I.ay
II.b
II.e
III.m
IV.a
IV.d
IV.t
IV.x
IV.af
IV.ag
V.g
VI.a
VI.i
VI.t
VII.a
VII.b
VIII.a
IX.a
IX.d
IX.r
IX.ab
IX.ac
X.a
X.c
X.d
X.e
X.f
X.i
X.j
X.l
X.m
X.o
X.p
X.u
X.w
X.ao
X.ap
X.ax
X.az
X.bj
XI.l
XI.v
XI.ad
XI.ar
XI.as
XI.av
XII.a
XII.c
XII.d
XII.f
XII.h
XII.n
XII.o
XII.s
XII.t
XII.ak
XII.az
XII.bd
XVI.k
XVI.v
XVI.w
XVI.bj
XVI.bk
XVI.bv
XVIII.a
XVIII.b
XVIII.c
XIX.a
XIX.b
XIX.d
XIX.e
XIX.f
XIX.j
XIX.o
XIX.x
XIX.ae
XIX.al
XIX.bx
XIX.co
XIX.cr
XIX.cv
XX.b
XX.c
XX.e
XX.g
XX.q
XX.r
Infliximab
I.a
I.b
I.c
I.d
I.e
I.g
I.x
I.z
II.e
III.a
IV.a
VI.a
VI.d
VII.a
VII.d
X.a
X.b
X.d
X.e
X.f
X.i
X.j
X.l
X.m
X.u
X.aj
X.at
XII.c
XII.d
XII.r
XII.bt
XVI.b
XIX.a
XIX.o
XIX.bo
XX.b
XX.c
XX.d
XX.e
XX.f
XX.g
XX.h
XX.n
XX.o
XX.q
XX.r
XX.x
XX.y
XX.ab
Ipilimumab
I.a
I.b
I.e
I.n
I.w
II.e
IV.d
VI.a
VI.m
VIII.e
IX.j
IX.r
IX.ab
X.a
X.e
X.i
X.l
X.m
X.n
X.q
X.ao
XII.c
XII.d
XII.ba
XII.bc
XVI.bk
XVIII.a
XIX.d
XIX.bv
XX.b
XX.c
Leukotriene receptor antagonists (LTRA)
I.c
X.e
X.j
X.u
Methimazole
III.a
III.b
III.d
IV.a
V.c
VI.b
VII.d
X.e
X.u
X.z
XI.l
Loading more…